北京若生智能科技有限公司
Drug Database
DO

doxorubicin (doxorubicin, Nanox / Doxonax)

✓ Approved

Nanox · TOP2A · 小分子

什么是 doxorubicin？

doxorubicin 是一种小分子，由Nanox研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)。

药物档案

商品名doxorubicin, Nanox, Doxonax
公司Nanox
药物类别小分子
分子靶点TOP2A
给药途径Injectable (Others)
状态Approved
来源： ClinicalTrials.gov, Nanox

作用机制

分子靶点

doxorubicin 作用于 1 个分子靶点：

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

doxorubicin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved

相关研究文献

PubMedNarra J2026-09-11

Global longitudinal strain and left ventricular ejection fraction for early detection of chemotherapy-related cardiac dysfunction in breast cancer: A prospective comparison of doxorubicin-based and paclitaxel- carboplatin regimens.

Faradilla Rizka R, Heriansyah Teuku T, Novita Novita N, Munirwan Haris H et al.

Left ventricular ejection fraction (LVEF) is widely used in routine practice to assess cardiotoxicity; however, reductions in LVEF often reflect relatively advanced myocardial damage. Global longitudinal strain (GLS) quantifies myocardial deformation and has demonstrated greater sensitivity for identifying early systolic dysfunction, yet comparative evidence on myocardial strain changes between doxorubicin-based regimens and non-anthracycline chemotherapy in breast cancer patients remains limited. The aim of this study was to compare changes in left ventricular GLS and LVEF between breast cancer patients receiving doxorubicin-based chemotherapy and those treated with paclitaxel- carboplatin regimens. A prospective cohort study was conducted among 106 women with histopathologically confirmed breast cancer, who were allocated to receive either a doxorubicin-based regimen (n=53) or a paclitaxel-carboplatin regimen (n=53). Transthoracic echocardiography was performed within seven days before chemotherapy initiation and repeated after four months. Left ventricular GLS was measured using two-dimensional speckle-tracking echocardiography from apical views and analyzed offline using the 17-segment model. Baseline GLS values did not differ significantly between the doxorubicin and paclitaxel-carboplatin groups (-20.47±0.45 vs -20.38±0.53; p=0.410). After four months, GLS was significantly reduced in the doxorubicin group compared with the paclitaxel-carboplatin group (-15.04±0.35 vs -19.54±0.50; p<0.001). The change in GLS (ΔGLS) was also greater in the doxorubicin group (5.43±0.12 vs 0.84±0.11; p<0.001). No significant differences were observed in LVEF before chemotherapy (55.26±1.78 vs 55.39±1.99; p=0.720), after chemotherapy (51.32±1.51 vs 51.60±1.64; p=0.359), or in ΔLVEF (p=0.484). In conclusion, doxorubicin-based chemotherapy was associated with early subclinical systolic dysfunction detectable by GLS before measurable LVEF decline, whereas paclitaxel-carboplatin was associated with relatively preserved myocardial deformation. These findings support the incorporation of strain imaging into routine cardiac surveillance for earlier identification and management of chemotherapy-related myocardial injury.

PMID 42724312
阅读全文 →
PubMedNanoscale advances2026-09-11

Dual-drug delivery system based on cubosomes for glioblastoma therapy: electrochemical, structural and biological characterization.

Dąbrowska Ewelina E, Gaweł Damian D, Godlewska Marlena M, Gajda Ewa E et al.

Monotherapy using a single drug exhibits significant limitations in the treatment of complex diseases, particularly cancer, where tumor heterogeneity often restricts therapeutic efficacy. Dual-drug delivery systems enable the co-administration of therapeutics with distinct and complementary mechanisms of action, offering a promising strategy to overcome these limitations. In this study, we developed a dual-drug delivery system based on lipid liquid-crystalline cubic phases (LCPs) co-loaded with temozolomide (TMZ) and doxorubicin (DOX). TMZ induces DNA alkylation, whereas DOX inhibits topoisomerase II, thereby reducing the likelihood of developing resistance by tumor. Electrochemical methods were employed to investigate drug release kinetics from mono- and dual-drug-loaded cubosomes and to detect any interactions between the drugs or with the lipid forming the carrier that affect the release behavior of each drug from the nanocarrier system. They also allowed monitoring of the hydrolysis of TMZ and proposal of the optimal ratio of drugs in the carrier, taking into account this degradation process. The simultaneous administration of TMZ and DOX may improve treatment efficacy through synergistic effects and permit dose reduction compared with monotherapy. The structural properties of the nanoparticles were characterized using small-angle X-ray scattering (SAXS) and dynamic light scattering (DLS). Biological evaluation demonstrated that combination treatment with a standard concentration of TMZ and a lower concentration of DOX resulted in improved therapeutic outcomes in A172 glioblastoma-derived and HeLa cell lines.

PMID 42724411
阅读全文 →
PubMedJournal of pathology and translational medicine2026-09-11

Ki-67 index and galectin-3 as surrogate markers for predicting disease-free survival in luminal-type breast carcinoma treated with neoadjuvant chemotherapy.

Lee Ho-Chang HC, Han Wonshik W, Im Seock-Ah SA, Park In Ae IA

Residual cancer burden (RCB) is an important marker for patients with breast carcinoma treated with neoadjuvant chemotherapy (NACT). However, the association between RCB and prognosis is relatively less significant in residual luminal-type breast carcinoma (LTBC). Associations between clinicopathological variables, including RCB class, and immunohistochemical (IHC) markers with disease-free survival (DFS) were analyzed. Expression of Ki-67, calreticulin, clusterin, galectin-3, mucin-1, and p27 was assessed in tissue microarray slides of 55 post-NACT resection specimens from LTBC patients treated with docetaxel and doxorubicin. Patients' age, pre-NACT progesterone receptor status, lymphovascular invasion, histologic grade, ypT category, ypN category, RCB class, and IHC markers were analyzed for their association with DFS using Kaplan-Meier analysis and Cox proportional hazards models. Twenty of the 55 patients developed recurrence or distant metastasis. A Ki-67 index > 2.7% and high galectin-3 expression were associated with shorter DFS on Kaplan-Meier analysis (p < .001 and p = .018, respectively). Other clinicopathological and IHC markers were not significantly associated with DFS. In the multivariate Cox proportional hazards model, a Ki-67 index > 2.7% (hazard ratio, 7.23; p < .001) and high galectin-3 expression (hazard ratio, 4.51; p = .007) remained independent predictors of shorter DFS. The Ki-67 index and high galectin-3 expression in post-NACT resection specimens may serve as surrogate markers for predicting recurrence in LTBC.

PMID 42723306
阅读全文 →
PubMedRSC pharmaceutics2026-09-10

Phosphatidylserine-based liposomes encapsulating DMX-5804 protect against doxorubicin-induced cardiotoxicity.

Tetterton-Kellner Jessica J, Miserendino Audreanna A, Tariq Imran I, Jensen Brian C BC et al.

Anthracycline induced cardiotoxicity is a significant problem for oncologists and cancer patients. The leading cause of non-cancer death in cancer patients and survivors is heart failure, which is frequently attributed to the exposure to chemotherapeutics like anthracyclines. The most notorious of these chemotherapeutics is doxorubicin, which causes cardiac contractile dysfunction, which in some cases is irreversible. In this study, we report the development of NanoDMX, a phosphatidylserine-containing liposomal formulation of DMX5804, a small molecule inhibitor of MAP4K4, and demonstrate that its administration prevents doxorubicin-induced left ventricular dysfunction in mice. Additionally, we demonstrate that DMX-5804 protects cardiomyocytes in vitro through a combination of mechanisms outside of the expected route of suppressing the JNK pathway. Overall, we demonstrate that the use of NanoDMX, a novel liposomal system using both DMX-5804 and phosphatidylserine, can prevent the damage induced by doxorubicin over the course of a single high dose in vivo model.

PMID 42719253
阅读全文 →
PubMedTissue & cell2026-09-10

Evaluation of the protective effects of Syzygium aromaticum L. against doxorubicin-induced cardiotoxicity in rats.

Shahinfar Zahra Z, Poorzand Hoorak H, Askari Vahid Reza VR, Khodadadi Hamid H et al.

Doxorubicin (DOX), a widely used anthracycline chemotherapy drug, has the potential to cause toxicity in multiple organs, particularly the myocardium. This study examines the cardioprotective effects of Syzygium aromaticum L. extract (SAE) in DOX-induced cardiotoxicity. This study involved 48 male Wistar rats (250-300 g), divided into (n = 8): Sham, Doxorubicin (DOX 2 mg/kg intraperitoneally every 48 h for 12 days), SAE groups (DOX plus SAE orally, 50, 100, and 200 mg/kg/day), and Vitamin E (DOX plus Vitamin E orally at 100 mg/kg/day) over a 20-day period, beginning four days before DOX administration. We revealed that DOX significantly lowered body weight, heart tissue weight, reduced glutathione (GSH), and interleukin (IL)-10 levels, while increasing lactate dehydrogenase (LDH), troponin, creatine kinase (CK-MB), malondialdehyde (MDA), TNF-α, IL-6, and TGF-β, as well as histopathological damage in heart tissue (q < 0.001). In contrast, treatment with all three doses of SAE and Vitamin E significantly reduced oxidative, inflammatory, and fibrotic markers, as well as histopathological injury, after DOX-induced cardiotoxicity (q < 0.05 to <0.001). In addition, DOX significantly increased left ventricular (LV) end-systolic diameter (LVESD) and LV end-diastolic diameter (LVEDD), while LV ejection fraction (LVEF) and LV fractional shortening (LVFS) were decreased considerably compared to the sham group (q < 0.001). In contrast, treatment involving SAE and vitamin E markedly decreased these echocardiographic markers (q < 0.05 to <0.001) compared to the DOX group. SAE extract markedly ameliorated cardiotoxicity caused by doxorubicin by demonstrating antioxidant, anti-inflammatory, and anti-fibrotic properties. Nonetheless, additional mechanistic studies, pharmacokinetic investigations, safety assessments, and clinical research is necessary to verify its efficacy.

PMID 42721759
阅读全文 →
PubMedMacromolecular bioscience2026-09-10

Living Biohybrid Hydrogels for Co-Delivery of Oxygen, Anti-Cancer Drugs, and Probiotics: Effects on Cancer and Healthy Cell Viability.

Süleymanzade Ulvi U, Şahin Tugba Ezgi TE, Demir Yagmur Damla YD, Yatar Yagmur Eylül YE et al.

In recent studies, oxygen (O2) delivery biomaterials have been developed to reduce hypoxia-induced problems in, e.g., tumor tissues. However, none of these studies have used inhibitory effects of probiotics in combination therapies with O2 and anticancer drugs for advanced cancer treatment applications. In this study, we report a new probiotic-enriched 3D-printed biomaterial (3D-BioHybrid-DOX/SPEP) that is capable of O2, probiotic, and acidic pH (pH 6.0) sensitive anticancer drug (Doxorubicin = DOX) co-release. 3D-BioHybrid-DOX/SPEP shows sustained O2 and pH-responsive anticancer drug release over 14 days. The release of short-chain fatty acids, including butyric acid, was detected on days 1 and 7 of incubation, indicating that the O2 delivery component of the system supports probiotic viability while mitigating the toxic effects of DOX. The CFU results show that the 3D-BioHybrid-DOX/SPEP supports probiotic viability at 1 and 7 days of incubation. In vitro cell experiments indicate that the healthy cell viability is ca. 2 times higher than cancer cells after 1 and 7 days of incubation at hypoxia conditions in 3D-BioHybrid-DOX/SPEP due to the co-administration of O2, DOX, and probiotics.

PMID 42721362
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多doxorubicin